Physician profile
Reshad Salam
NPI 1467024448
$2,181.97
in general payments reported to CMS, 2019-2025
17 companies · $22.28 in 2025
The $22.28 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $766 · 2023: $739 · 2024: $655 · 2025: $22.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,366 · Education: $50.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,365.85 |
| Education | $50.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $387.90 | 2022-2023 | Skyrizi |
| Regeneron Healthcare Solutions, INC. | $355.69 | 2022-2024 | Dupixent |
| Janssen Biotech, INC. | $348.00 | 2023-2024 | Stelara, Tremfya |
| Janssen Scientific Affairs, LLC | $155.66 | 2024 | Stelara, Tremfya |
| Ardelyx, INC. | $130.20 | 2023 | Ibsrela |
| Genzyme Corporation | $124.74 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.33 | 2022 | |
| Intercept Pharmaceuticals, INC. | $116.19 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $114.26 | 2022 | |
| Gilead Sciences, INC. | $107.10 | 2024 | Epclusa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $50.38 | 2022-2023 | Lifevest |
| Mallinckrodt Hospital Products INC. | $50.14 | 2023 | Terlivaz |
| Takeda Pharmaceuticals U.S.A., INC. | $41.52 | 2022 | |
| Neurocrine Biosciences, INC. | $24.15 | 2024 | Ingrezza |
| Astrazeneca Pharmaceuticals LP | $22.28 | 2025 | Wainua |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $18.96 | 2024 | Onpattro |
| Genentech USA, INC. | $17.47 | 2024 | Enspryng, Ocrevus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reshad Salam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.